Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Gemcitabine (Primary) ; Capecitabine; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms TIGeR-PaC
- Sponsors RenovoRx
- 12 Jul 2024 Planned number of patients changed from 320 to 190.
- 12 Jul 2024 Planned End Date changed from 1 Sep 2023 to 1 Sep 2026.
- 12 Jul 2024 Planned primary completion date changed from 1 Sep 2022 to 1 Jun 2026.